125IN - Hepatocellular carcinoma in the EU

Date 01 October 2012
Event ESMO Congress 2012
Session ESMO-JSMO Joint symposium: Recent advances in the treatment of GI tract and liver cancer in the EU and Japan
Topics Hepatobiliary Cancers
Presenter Jordi Bruix
Authors J. Bruix
  • Liver Unit, HOSPITAL CLINIC Y PROVINCIAL DE BARCELONA, 08036 - BARCELONA/ES

Abstract

The incidence of liver cancer varies across Europe. However, while figures have stabilised in Italy and Spain, Northern countries present a slight increase in recent years. In most cases, liver cancer appears in the background of chronic liver disease related to hepatitis C or B, infection and alcoholism, among other risk factors. Current data show that hepatocellular carcinoma is the leading cause of death in patients with cirrhosis and that the incidence of intrahepatic cholangiocarcinoma is on the rise. Because of its clinical relevance all scientific associations have developed practice guidelines to inform patients, physicians and regulatory agents about the established diagnostic and therapeutic procedures. Non-invassive diagnostic criteria have been accepted and in almost all documents the recommended strategy for staging and treatment indication is the BCLC model. Following it, patients diagnosed with HCC are stratified into stages for which different treatment options are to be considered.

References

1. Jelic S, Sotiropoulos GC; ESMO Guidelines Working GroupHepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 ;21 Suppl 5:v59–64

2. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011 Mar 1;53 (3):1020–2.

3. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56 (4):908–43.

4. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379 (9822):1245–55.

Disclosure

The author has declared no conflicts of interest.